

RECEIVED

MAY 08 2002

TECH CENTER 1600/2900

PATENT

1646  
#6  
DmT  
5-1482

DOCKET NO.: AREN-0308

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE



In Re Application of:

Ruoping Chen et al.

Serial No.: 09/995,225

Group Art Unit: 1646

Filing Date: November 26, 2001

Examiner: Unknown

For: ENDOGENOUS AND NON-ENDOGENOUS VERSIONS OF HUMAN G  
PROTEIN-COUPLED RECEPTORS

DATE OF DEPOSIT:

Apr. 25, 2002

I HEREBY CERTIFY THAT THIS PAPER IS BEING  
DEPOSITED WITH THE UNITED STATES POSTAL  
SERVICE AS FIRST CLASS MAIL, POSTAGE PREPAID  
ON THE DATE INDICATED ABOVE AND IS ADDRESSED  
TO THE ASSISTANT COMMISSIONER FOR PATENTS,  
WASHINGTON, DC 20231.

Gwilym J.O. Attwell  
TYPED NAME: Gwilym J.O. Attwell  
REGISTRATION NO.: 45,449

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).



In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first office action after the filing of request for continued examination under §1.114, no additional fee is required.

- ☐ In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with ☐the first or ☐second After Final Submission, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or before an action that otherwise closes prosecution in the application, therefore:
- ☐ Certification in Accordance with §1.97(e) is attached; or
- ☐ The fee of \$180.00 as set forth in §1.17(p) is attached.
- ☐ In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); and the submission fee of \$180.00 as set forth in §1.17(p).
- ☐ Copies of each of the references listed on the attached Form PTO-1449 are enclosed herewith.
- ☒ Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT:
- ☒ In view of the voluminous nature of references **EV, EW and GX**, and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.

☒ In accordance with §1.98(d), copies of the following references listed on the attached Form PTO-1449 are not enclosed herewith because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application(s) for which a claim for priority under 35 U.S.C. §120 have been made in the instant application:

☒ Copies of references **AA-EQ, FC-GN, GP, G Q and GY-HJ** listed on the attached Form PTO-1449 were previously cited by or submitted to the Patent and Trademark Office in prior application Serial No. **09/170,496**, filed **October 13, 1998**.


☐ If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050.

This form is submitted in duplicate.

English language abstracts were provided for those listed references which are not in the English language.

Date: *April 25, 2002*

  
\_\_\_\_\_  
Gwilym J.O. Attwell  
Registration No. 45,449

WOODCOCK WASHBURN LLP  
One Liberty Place - 46th Floor  
Philadelphia, PA 19103  
Telephone: (215) 568-3100  
Facsimile: (215) 568-3439



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	TECH CENTER 1600/2900 MAY 08 2002
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>AA</b>	Alla, S.A. et al., "Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies," <i>J. Biol. Chem.</i> , <b>1996</b> , <i>271</i> , 1748-1755		
	<b>AB</b>	Advenier, C. et al., "Effects on the isolated human bronchus of SR 48968, a potent and selective nonpeptide antagonist of the neurokinin A (NK <sub>2</sub> ) receptors," <i>Am. Rev. Respir. Dis.</i> , <b>1992</b> , <i>146</i> (5, Pt. 1), 1177-1181		
	<b>AC</b>	Alexander, W.S. et al., "Point mutations within the dimer interfact homology domain of c-Mpl induce constitutive receptor activity and tumorigenicity," <i>EMBO J.</i> , <b>1995</b> , <i>14</i> (22), 5569-5578		
	<b>AD</b>	Arvanitakis, L. et al., "Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation," <i>Nature</i> , <b>1997</b> , <i>385</i> , 347-349		
	<b>AE</b>	Barker, E.L. et al., "Constitutively active 5-hydroxytryptamine <sub>2C</sub> receptors reveal novel inverse agonist activity of receptor ligands," <i>J. Biol. Chem.</i> , <b>1994</b> , <i>269</i> (16), 11687-11690		
	<b>AF</b>	Baxter, G., "5-HT <sub>2</sub> receptors: a family re-united?" <i>Trends Pharmacol. Sci.</i> , <b>1995</b> , <i>16</i> , 105-110		
	<b>AG</b>	Besmer, P. et al., "A new acute transforming feline retrovirus and relationship of its oncogene <i>v-kit</i> with the protein kinase gene family," <i>Nature</i> , <b>1986</b> , <i>320</i> , 415-421		
	<b>AH</b>	Blin, N. et al., "Mapping of single amino acid residues required for selective activation of G <sub>q/11</sub> by the m3 muscarinic acetylcholine receptor," <i>J. Biol. Chem.</i> , <b>1995</b> , <i>270</i> , 17741-17748		
	<b>AI</b>	Bond, R.A. et al., "Inverse agonists and G-protein-coupled receptors," in <i>Receptor-Based Drug Design</i> , Leff, P. (ed.), New York, M. Dekker, <b>1998</b> , 363-377		
	<b>AJ</b>	Boone, C. et al., "Mutations that alter the third cytoplasmic loop of the a-factor receptor lead to a constitutive and hypersensitive phenotype," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , <i>90</i> (21), 9921-9925		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	TECH CENTER 1600/2300 MAY 08 2002
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>AK</b>	Burstein, E.S. et al., "Constitutive activation of chimeric m2/m5 muscarinic receptors and delineation of G-protein coupling selectivity domains," <i>Biochem. Pharmacol.</i> , <b>1996</b> , 51(4), 539-544		
	<b>AL</b>	Burstein, E.S. et al., "Amino acid side chains that define muscarinic receptor/G-protein coupling. Studies of the third intracellular loop," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(6), 2882-2885		
	<b>AM</b>	Burstein, E.S. et al., "Constitutive activation of muscarinic receptors by the G-protein G <sub>q</sub> ," <i>FEBS Lett.</i> , <b>1995</b> , 363(3), 261-263		
	<b>AN</b>	Bylund, D., "International union of pharmacology nomenclature of adrenoceptors," <i>Pharmacol. Rev.</i> , <b>1994</b> , 46, 121-136		
	<b>AO</b>	Casey, C. et al., "Constitutively active mutant 5-HT <sub>2A</sub> serotonin receptors: inverse agonist activity of classical 5HT <sub>2A</sub> antagonists," <i>Soc. Neurosci.</i> , <b>1996</b> , Abstract #699.10		
	<b>AP</b>	Cheatham, B. et al., "Substitution of the <i>erbB-2</i> oncoprotein transmembrane domain activates the insulin receptor and modulates the action of insulin-receptor substrate 1," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90, 7336-7340		
	<b>AQ</b>	Chen, J. et al., "Tethered Ligand Library for Discovery of Peptide Agonists," <i>J. Biol. Chem.</i> , <b>1995</b> , 270, 23398-23401		
	<b>AR</b>	Chen, T.S. et al., "Microbial hydroxylation and glucuronidation of the angiotensin II (AII) receptor antagonist MK 954," <i>J. Antibiot. (Tokyo)</i> , <b>1993</b> , 46(1), 131-134		
	<b>AS</b>	Chen, W. et al., "A colorimetric assay for measuring activation of G <sub>s</sub> - and G <sub>q</sub> -coupled signaling pathways," <i>Anal. Biochem.</i> , <b>1995</b> , 226(2), 349-354		
	<b>AT</b>	Chidiac, P. et al., "Inverse agonist activity of $\beta$ -adrenergic antagonists," <i>J. Pharm. Exp. Ther.</i> , <b>1994</b> , 45, 490-499		
	<b>AU</b>	Clozel, M. et al., "In vivo pharmacology of Ro 46-2005, the first synthetic nonpeptide endothelin receptor antagonist: implications for endothelin physiology," <i>J. Cardiovas. Pharmacol.</i> , <b>1993</b> , 22(Suppl. 8), S377-S379		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	TECH CENTER 1600/2900 MAY 08 2002
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>AV</b>	Collesi, C. et al., "A splicing variant of the <i>RON</i> transcript induces constitutive tyrosine kinase activity and an invasive phenotype," <i>Mol. Cell. Biol.</i> , <b>1996</b> , 16(2), 5518-5526		
	<b>AW</b>	Cooper, C.S. et al., "Molecular cloning of a new transforming gene from a chemically transformed human cell line," <i>Nature</i> , <b>1984</b> , 311, 29-33		
	<b>AX</b>	De Dios, I. et al., "Effect of L-364,718 (CCK Receptor Antagonist) on Exocrine Pancreatic Secretion of Hydrocortison-Treated Rats," <i>Pancreas</i> , <b>1994</b> , 9(2), 212-218		
	<b>AY</b>	Desbois-Mouthon, C. et al., "Deletion of Asn <sup>281</sup> in the $\alpha$ -subunit of the human insulin receptor causes constitutive activation of the receptor and insulin desensitization," <i>J. Clin. Endocrinol. Metab.</i> , <b>1996</b> , 81(2), 719-727		
	<b>AZ</b>	Di Renzo, M.F. et al., "Expression of the Met/HGF receptor in normal and neoplastic human tissues," <i>Oncogene</i> , <b>1991</b> , 6(11), 1997-2003		
	<b>BA</b>	Di Renzo, M.F. et al., "Overexpression of the c-MET/HGF receptor gene in human thyroid carcinomas," <i>Oncogene</i> , <b>1992</b> , 7, 2549-2553		
	<b>BB</b>	Duprez, L. et al., "Germline mutations of the thyrotropin receptor gene cause non-autoimmune autosomal dominant hyperthyroidism," <i>Nature Genetics</i> , <b>1994</b> , 7, 396-401		
	<b>BC</b>	Eggerickx, D. et al., "Molecular Cloning of an Orphan G-Protein-Coupled Receptor that Constitutively Activates Adenylate Cyclase," <i>Biochem. J.</i> , <b>1995</b> , 309, 837-843		
	<b>BD</b>	Evans, B.E. et al., "Orally Active, Nonpeptide Oxytocin Antagonists," <i>J. Med. Chem.</i> , <b>1992</b> , 35, 3919-3927		
	<b>BE</b>	Fu, M. et al., "Functional autoimmune epitope on $\alpha_1$ -adrenergic receptors in patients with malignant hypertension," <i>Lancet</i> , <b>1994</b> , 344, 1660-1663		
	<b>BF</b>	Furitsu, T. et al., "Identification of Mutations in the Coding Sequence of the Proto-oncogene c-kit in a Human Mast Cell Leukemia Cell Line Causing Ligand-independent Activation of c-kit Product," <i>J. Clin. Invest.</i> , <b>1993</b> , 92, 1736-1744		
	<b>BG</b>	Gellai, M. et al., "Nonpeptide Endothelin Receptor Antagonists V: Prevention and Reversal of Acute Renal Failure in the Rat by SB 209670," <i>J. Pharm. Exp. Therap.</i> , <b>1995</b> , 275(1), 200-206		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>

RECEIVED  
MAY 08 2002  
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BH	Gitter, B. et al., "Pharmacological Characterization of LY303870: A Novel Potent and Selective Nonpeptide Substance P (Neurokinin-1) Receptor Antagonist," <i>J. Pharm. Exp. Therp.</i> , <b>1995</b> , 275(2), 737-744	
BI	Gouilleux-Gruart, V. et al., "STAT-Related Transcription Factors are Constitutively Activated in Peripheral Blood Cells from Acute Leukemia Patients," <i>Blood</i> , <b>1996</b> , 87(5), 1692-1697	
BJ	Hansson, J.H. et al., "Hypertension caused by a truncated epithelial sodium channel $\gamma$ subunit: genetic heterogeneity of Liddle syndrome," <i>Nat. Genet.</i> , <b>1995</b> , 11(1), 76-82	
BK	Hasegawa, H. et al., "Two Isoforms of the Prostaglandin E Receptor EP3 Subtype Different in Agonist-independent Constitutive Activity," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(4), 1857-1860	
BL	Hendler, F. et al., "Human Squamous Cell Lung Cancers Express Increased Epidermal Growth Factor Receptors," <i>J. Clin. Invest.</i> , <b>1984</b> , 74, 647-651	
BM	Herrick-Davis, K. et al., "Constitutively Active 5HT <sub>2C</sub> Serotonin Receptor Created by Site-Directed Mutagenesis," <i>Soc. Neurosci.</i> , Abstract No. 699.18	
BN	Hieble, J., "International union of pharmacology. X. Recommendation for nomenclature of 1-adrenoceptors," <i>Pharm. Rev.</i> , <b>1995</b> , 47, 267-270	
BO	Hill, S., "Distribution, Properties, and Functional Characteristics of Three Classes of Histamine Receptor," <i>Am. Soc. Pharm. Exp. Therap.</i> , <b>1990</b> , 42(1), 45-83	
BP	Högger, P. et al., "Activating and Inactivating Mutations in - and C-terminal i3 Loop Junctions of Muscarinic Acetylcholine Hm1 Receptors," <i>J. Biol. Chem.</i> , <b>1995</b> , 270(13), 7405-7410	
BQ	Ikeda, H. et al., "Expression and Functional Role of the Proto-oncogene <i>c-kit</i> in Acute Myeloblastic Leukemia Cells," <i>Blood</i> , <b>1991</b> , 78(11), 2962-2968	
BR	Imura, R. et al., "Inhibition by HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin, of atrial natriuretic peptide-induced relaxation of isolated rabbit aorta through the blockade of guanylyl cyclase-linked receptors," <i>Mol. Pharm.</i> , <b>1992</b> , 42, 982-990	

EXAMINER	DATE CONSIDERED
----------	-----------------



RECEIVED  
MAY 08 2002  
TECH CENTER 1600/2900


<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
	Applicant <b>Ruoping Chen, et al.</b>	
	Filing Date <b>November 26, 2001</b>	Group <b>1646</b>

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

<b>BS</b>	Jakubik, J. et al., "Constitutive activity of the M <sub>1</sub> -M <sub>4</sub> subtypes of muscarinic receptors in transfected CHO cells and of muscarinic receptors in the heart cells revealed by negative antagonists," <i>FEBS Letts.</i> , <b>1995</b> , 377, 275-279
<b>BT</b>	Kjelsberg, M.A. et al., "Constitutive activation of the $\alpha_{1B}$ -adrenergic receptor by all amino acid substitutions at a single site," <i>J. Biol. Chem.</i> , <b>1992</b> , 267(3), 1430-1433
<b>BU</b>	Knapp, R. et al., "Molecular biology and pharmacology of cloned opioid receptors," <i>FASEB J.</i> , <b>1995</b> , 9, 516-525
<b>BV</b>	Kosugi, S. et al., "Characterization of heterogeneous mutations causing constitutive activation of the luteinizing hormone receptor in familial male precocious puberty," <i>Human Mol. Genetics</i> , <b>1995</b> , 4(2), 183-188
<b>BW</b>	Kosugi, S. et al., "Identification of Thyroid-Stimulating Antibody-Specific Interaction Sites in the N-Terminal Region of the Thyrotropin Receptor," <i>Mol. Endocrinology</i> , <b>1993</b> , 7, 114-130
<b>BX</b>	Kraus, M. et al., "Demonstration of ligand-dependent signaling by the <i>erbB-3</i> tyrosine kinase and its constitutive activation in human breast tumor cells," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1993</b> , 90, 2900-2904
<b>BY</b>	Kudlacz, E. et al., "In Vitro and In Vivo Characterization of MDL 105,212A, a Nonpeptide NK-1/NK-2 Tachykinin Receptor Antagonist," <i>J. Pharm. Exp. Therap.</i> , <b>1996</b> , 277(2), 840-851
<b>BZ</b>	Kuriu, A. et al., "Proliferation of Human Myeloid Leukemia Cell Line Associated with the Tyrosine-Phosphorylation and Activation of the Proto-oncogene <i>c-kit</i> Product," <i>Blood</i> , <b>1991</b> , 78(11), 2834-2840
<b>CA</b>	Labbé-Jullié, C. et al., "Effect of the nonpeptide neurotensin antagonist, SR 48692, and two enantiomeric analogs, SR 48527 and SR 49711, on neurotension binding and contractile responses in guinea pig ileum and colon," <i>J. Pharm. Exp. Therap.</i> , <b>1994</b> , 271(1), 267-276
<b>CB</b>	Latronico, A. et al., "A novel mutation of the luteinizing hormone receptor gene causing male gonadotropin-independent precocious puberty," <i>J. Clin. Endocrinol. Metabl.</i> , <b>1995</b> , 80(8), 2490-2494

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------






<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>

RECEIVED  
MAY 08 2002  
TECH CENTER 1600/2900

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
CC	Laue, L. et al., "Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty," <i>Proc. Natl. Acad. Sci USA</i> , <b>1995</b> , 92, 1906-1910	
CD	Løvlie, R. et al., "The Ca <sup>2+</sup> -sensing receptor gene (PCAR1) mutation T151M in isolated autosomal dominant hypoparathyroidism," <i>Hum. Genet</i> , <b>1996</b> , 98, 129-133	
CE	Lefkowitz, R. et al., "Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins," <i>Trends Pharmacol. Sci.</i> , <b>1993</b> , 14, 303-307	
CF	Libermann, T. et al., "Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin," <i>Nature</i> , <b>1985</b> , 313, 144-147	
CG	Liu, C. et al., "Overexpression of c-met proto-oncogene but not epidermal growth factor receptor or c-erbB-2 in primary human colorectal carcinomas," <i>Oncogene</i> , <b>1992</b> , 7, 181-185	
CH	Liu, J. et al., "Molecular mechanisms involved in muscarinic acetylcholine receptor-mediated G protein activation studied by insertion mutagenesis," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(11), 6172-6178	
CI	Lonardo, F. et al., "The normal erbB-2 product is an atypical receptor-like tyrosine kinase with constitutive activity in the absence of ligand," <i>New Biologist</i> , <b>1990</b> , 2(11), 992-1003	
CJ	Maenhaut, C. et al., "RDC8 codes for an adenosine A2 receptor with physiological constitutive activity," <i>Biochem. Biophys. Res. Comm.</i> , <b>1990</b> , 173(3), 1169-1178	
CK	Mann, J. et al., "Increased serotonin <sub>2</sub> and β-adrenergic receptor binding in the frontal cortices of suicide victims," <i>Arch. Gen. Psychiatry</i> , <b>1986</b> , 43, 954-959	
CL	Martone, R.L. et al., "Human CRF receptor chimeras: Mapping of ligand binding determinants," 26th Meeting of the Society of Neuroscience, Washington, D.C. November 16-21, <b>1996</b> , Abstract No. 609.8	
CM	Magnusson, Y. et al., "Autoimmunity in idiopathic dilated cardiomyopathy," <i>Circulation</i> , <b>1994</b> , 89, 2760-2767	

EXAMINER	DATE CONSIDERED
----------	-----------------



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	TECH CENTER 1600/2900 MAY 08 2002
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>CN</b>	Matus-Leibovitch, N. et al., "Truncation of the thyrotropin-releasing hormone receptor carboxyl tail causes constitutive activity and leads to impaired responsiveness in <i>Xenopus</i> Oocytes and AtT20 Cells," <i>J. Biol. Chem.</i> , <b>1995</b> , 270(3), 1041-1047		
	<b>CO</b>	Myles, G.M. et al., "Tyrosine 569 in the c-Fms juxtamembrane domain is essential for kinase activity and macrophage colony-stimulating factor-dependent internalization," <i>Mol. Cell. Biol.</i> , <b>1994</b> , 14(7), 4843-4854		
	<b>CP</b>	Nanevicz, T. et al., "Thrombin receptor activating mutations," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(2), 702-706		
	<b>CQ</b>	Natali, P.G. et al., "Expression of the c-Met/HGF receptor in human melanocytic neoplasms: demonstration of the relationship to malignant melanoma tumour progression," <i>Br. J. Cancer</i> , <b>1993</b> , 68, 746-749		
	<b>CR</b>	Neilson, K.M. et al., "Constitutive activation of fibroblast growth factor receptor-2 by a point mutation associated with Crouzon syndrome," <i>J. Biol. Chem.</i> , <b>1995</b> , 270(44), 26037-26040		
	<b>CS</b>	Oda, S. et al., "Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist of microbial origin. II. Restoration by HS-142-1 of ANP-induced inhibition of aldosterone production in adrenal glomerulosa cells," <i>J. Pharm. Exp. Ther.</i> , <b>1992</b> , 263(1), 241-245		
	<b>CT</b>	O'Dowd, B.F. et al., "Site-directed mutagenesis of the cytoplasmic domains of the human $\beta$ 2-adrenergic receptor," <i>J. Biol. Chem.</i> , <b>1988</b> , 263(31), 15985-15992		
	<b>CU</b>	Offermanns, S. et al., " $G\alpha_{15}$ and $G\alpha_{16}$ Couple a Wide Variety of Receptors to Phospholipase C," <i>J. Biol. Chem.</i> , <b>1995</b> , 270, 15175-15180		
	<b>CV</b>	Palkowitz, A.D. et al., "Structural evolution and pharmacology of a novel series of triacid angiotensin II receptor antagonists," <i>J. Med. Chem.</i> , <b>1994</b> , 37, 4508-4521		
	<b>CW</b>	Parent, J. et al., "Mutations of two adjacent amino acids generate inactive and constitutively active forms of the human platelet-activating factor receptor," <i>J. Biol. Chem.</i> , <b>1996</b> , 271(14), 7949-7955		
	<b>CX</b>	Parfitt, A.M. et al., "Hypercalcemia due to constitutive activity of the parathyroid hormone (PTH)/PTH-related peptide receptor: comparison with primary hyperparathyroidism," <i>J. Clin. Endocr. Metabl.</i> , <b>1996</b> , 81, 3584-3588		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		



Sheet 8 of 18

RECEIVED

MAY 08 2002

TECH CENTER 1600/2900

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>CY</b>	Parma, J. et al., "Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas," <i>Nature</i> , <b>1993</b> , 365, 649-651	
	<b>CZ</b>	Pei, G. et al., "A constitutive active mutant $\beta_2$ -adrenergic receptor is constitutively desensitized and phosphorylated," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1994</b> , 91, 2699-2702	
	<b>DA</b>	Pendley, C.E. et al., "The gastrin/cholecystokinin-B receptor antagonist L-365,260 reduces basal acid secretion and prevents gastrointestinal damage induced by aspirin, ethanol and cysteamine in the rat," <i>J. Pharmacol. Exp. Ther.</i> , <b>1993</b> , 265(3), 1348-1354	
	<b>DB</b>	Peroutka, S., "Serotonin receptor subtypes. Their evolution and clinical relevance," <i>CNS Drugs</i> , <b>1995</b> , 4 (Suppl. 1), 18-27	
	<b>DC</b>	Pettibone, D.J. et al., "Development and pharmacological assessment of novel peptide and nonpeptide oxytocin antagonists," <i>Regul. Pept.</i> , <b>1993</b> , 45, 289-293	
	<b>DD</b>	Prat, M.P. et al., "The receptor encoded by the human c-Met oncogene is expressed in hepatocytes, epithelial cells and solid tumors," <i>Int. J. Cancer</i> , <b>1991</b> , 49, 323-328	
	<b>DE</b>	Prezeua, L. et al., "Changes in the carboxy-terminal domain of metabotropic glutamate receptor 1 by alternate splicing generate receptors with differing agonist-independent activity," <i>Mol. Pharmacol.</i> , <b>1996</b> , 49, 422-429	
	<b>DF</b>	Rakovska, A. et al., "Effect of loxiglumide (CR 1505) on CCK-induced contractions and $^3\text{H}$ -acetylcholine release from guinea-pig gallbladder," <i>Neuropeptides</i> , <b>1993</b> , 25(5), 271-276	
	<b>DG</b>	Ren, Q. et al., "Constitutive active mutants of the $\alpha_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , <b>1993</b> , 268, 16483-16487	
	<b>DH</b>	Reynolds, E.E. et al., "Pharmacological characterization of PD 156707, an orally active $\text{ET}_A$ receptor antagonist," <i>J. Pharmacol. Exp. Ther.</i> , <b>1995</b> , 273(3), 1410-1417	
	<b>DI</b>	Robbins, L.S. et al., "Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function," <i>Cell</i> , <b>1993</b> , 72, 827-834	
	<b>DJ</b>	Rong, S. et al., "Met expression and sarcoma tumorigenicity," <i>Cancer</i> , <b>1993</b> , 53(22), 5355-5360	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



RECEIVED

TECH CENTER 1600/2900

MAY 08 2002

**Form PTO-1449 Modified**

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Docket No.  
**AREN-0308**

Serial No.  
**09/995,225**

Applicant  
**Ruoping Chen, et al.**

Filing Date  
**November 26, 2001**

Group  
**1646**

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	<b>DK</b>	Samama, P. et al., "A mutation-induced activation state of the $\beta_2$ -adrenergic receptor," <i>J. Biol. Chem.</i> , <b>1993</b> , 268(7), 4625-4636
	<b>DL</b>	Sautel, M. et al., "Neuropeptide Y and the nonpeptide antagonist BIBP 3226 share an overlapping binding site at the human Y1 receptor," <i>Am. Soc. Pharm. Exp. Ther.</i> , <b>1996</b> , 50, 285-292
	<b>DM</b>	Sawutz, D.G. et al., "Pharmacology and structure-activity relationships of the nonpeptide bradykinin receptor antagonist WIN 64338," <i>Can. J. Physiol. Pharmacol.</i> , <b>1995</b> , 73, 805-811
	<b>DN</b>	Scheer, A. et al., "Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation," <i>J. Rec. Signal Transduct. Res.</i> , <b>1997</b> , 17(1-3), 57-73
	<b>DO</b>	Scheer, A. et al., "The activation process of the $\alpha_{1B}$ -adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1997</b> , 94, 808-813
	<b>DP</b>	Schwinn, D.A. et al., "Cloning and pharmacological characterization of human <i>Alpha</i> -1 adrenergic receptors: sequence corrections and direct comparison with other species homologues," <i>J. Pharmacol.</i> , <b>1995</b> , 272(1), 134-142
	<b>DQ</b>	Schild, L. et al., "A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the <i>Xenopus laevis</i> oocyte expression system," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1995</b> , 92, 5699-5703
	<b>DR</b>	Seeman, P. et al., "Dopamine receptor pharmacology," <i>Trends Pharmacol. Sci.</i> , <b>1994</b> , 15, 264-270
	<b>DS</b>	Seeman, P. et al., "Dopamine D4 receptors elevated in schizophrenia," <i>Nature</i> , <b>1993</b> , 365, 441-445
	<b>DT</b>	Serradeil-Le Gal, C. et al., "Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin $V_{1a}$ receptors," <i>J. Clin. Invest.</i> , <b>1993</b> , 92, 224-231
	<b>DU</b>	Sharif, M. et al., "Malignant transformation by G protein-coupled hormone receptors," <i>Mol. Cell. Endocrinology</i> , <b>1994</b> , 100, 115-119

**EXAMINER**

**DATE CONSIDERED**



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	MAY 08 2002 TECH CENTER 1600/2900
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>DV</b>	Showers, M.O. et al., "Activation of the erythropoietin receptor by the Friend spleen focus-forming virus gp55 glycoprotein induces constitutive protein tyrosine phosphorylation," <i>Blood</i> , <b>1992</b> , 80(12), 3070-3078		
	<b>DW</b>	Skinner, R.H. et al., "Direct measurement of the binding of RAS to neurofibromin using scintillation proximity assay," <i>Anal. Biochem.</i> , <b>1994</b> , 223, 259-265		
	<b>DX</b>	Slamon, D.J. et al., "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ <i>neu</i> oncogene," <i>Science</i> , <b>1987</b> , 235, 177-181		
	<b>DY</b>	Slamon, D. et al., "Studies of the HER-2/ <i>neu</i> proto-oncogene in human breast and ovarian cancer," <i>Science</i> , <b>1989</b> , 244, 707-712		
	<b>DZ</b>	Salomon, Y. et al., "A highly sensitive adenylate cyclase assay," <i>Anal. Biochem.</i> , <b>1974</b> , 58, 541-548		
	<b>EA</b>	Spiegel, A.M., "Defects in G protein-coupled signal transduction in human disease," <i>Ann. Rev. Physiol.</i> , <b>1995</b> , 58, 143-170		
	<b>EB</b>	ter Laak, A. et al., "Modelling and mutation studies on the histamine H <sub>1</sub> -receptor agonist binding site reveal different binding modes for H <sub>1</sub> -agonists: Asp <sup>116</sup> (TM3) has a constitutive role in receptor stimulation," <i>J. Computer-Aided Mol. Design</i> , <b>1995</b> , 9, 319-330		
	<b>EC</b>	Tiberi, M. et al., "High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype," <i>J. Biol. Chem.</i> , <b>1994</b> , 269(45), 27925-27931		
	<b>ED</b>	Tsujimura, T. et al., "Constitutive activation of <i>c-kit</i> in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain," <i>Blood</i> , <b>1996</b> , 87(1), 273-283		
	<b>EE</b>	Wang, Z. et al., "Constitutive $\mu$ opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence," <i>Life Sci.</i> , <b>1994</b> , 54(20), 339-350		
	<b>EF</b>	Watowich, S.S. et al., "Homodimerization and constitutive activation of the erythropoietin receptor," <i>Proc. Natl. Acad. Sci USA</i> , <b>1992</b> , 89, 2140-2144		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>	<b>RECEIVED</b>  MAY 08 2002  TECH CENTER 1800/2900
		Applicant <b>Ruoping Chen, et al.</b>		
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>				
	<b>EG</b>	Weber-Nordt, R.M. et al., "Constitutive activation of STAT proteins in primary lymphoid and myeloid leukemia cells and in Epstein-Barr virus (EBV)-related lymphoma cell lines," <i>Blood</i> , <b>1996</b> , 88(3), 809-816		
	<b>EH</b>	Webster, M.K. et al., "Constitutive activation of fibroblast growth factor receptor 3 by the transmembrane point mutation found in achondroplasia," <i>EMBO J.</i> , <b>1996</b> , 15, 520-527		
	<b>EI</b>	Xu, Y. et al., "Characterization of epidermal growth factor receptor gene expression in malignant and normal human cell lines," <i>Proc. Natl. Acad. Sci. USA</i> , <b>1984</b> , 81, 7308-7312		
	<b>EJ</b>	Yamada, K. et al., "Substitution of the insulin receptor transmembrane domain with the <i>c-neu/erbB2</i> transmembrane domain constitutively activates the insulin receptor kinas <i>in vitro</i> ," <i>J. Biol. Chem.</i> , <b>1992</b> , 267(18), 12452-12461		
	<b>EK</b>	Zhang, S. et al., "Identification of Dynorphins as Endogenous Ligands for an Opioid Receptor-Like Orphan Receptor," <i>J. Biol. Chem.</i> , <b>1995</b> , 270, 22772-22776		
	<b>EL</b>	Zhen, Z. et al., "Structural and functional domains critical for constitutive activation of the HGF-receptor ( <i>Met</i> )," <i>Oncogene</i> , <b>1994</b> , 9, 1691-1697		
	<b>EM</b>	Bergsma, D.J., et al., "Cloning and characterization of a human angiotensin II type 1 receptor," <i>Biochem. &amp; Biophys. Res. Comm.</i> , <b>1992</b> , XP-002145165, 183(3), 989-995		
	<b>EN</b>	Gantz, I. et al., "Molecular Cloning of a Novel Melanocortin Receptor," <i>J. Biol. Chem.</i> , <b>1993</b> , 268(11), 8246-8250		
	<b>EO</b>	Groblewski, T., et al., "Mutation of Asn <sup>111</sup> in the third transmembrane domain of the AT <sub>1a</sub> angiotensin II receptor induces its constitutive activation," <i>J. Biol. Chem.</i> , <b>1997</b> , XP-002145162, 272(3), 1822-1826		
	<b>EP</b>	Koike, G., et al., "Human type 2 angiotensin II receptor gene: cloned, mapped to the X chromosome, and its mRNA is expressed in the human lung," <i>Biochem. And Biophys. Res. Comm.</i> , <b>1994</b> , XP-002145166, 203(3), 1842-1850		
	<b>EQ</b>	Kyaw, H., et al., "Cloning, characterization, and mapping of human homolog of mouse T-cell death-associated gene," <i>DNA and Cell Biology</i> , <b>1998</b> , XP000929737, 17(6), 493-500		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>		




RECEIVED

MAY 08 2002  
TECH CENTER 1600/2900

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>ER</b>	Forman, B.M., et al., "Androstane Metabolites Bind to and Deactivate the Nuclear receptor CAR- $\beta$ ", <i>Nature</i> , <b>1998</b> , 395, pp. 612-615	
	<b>ES</b>	Itoh, H. et al., <i>Proc. Natl. Acad. Sci. USA</i> , <b>1986</b> , Vol. 83, pp. 3776	
	<b>ET</b>	Kenakin, T., <i>Life Sciences</i> , <b>1988</b> , Vol. 43, pp. 1095	
	<b>EU</b>	McKee, K. et al., "Cloning and Characterization of Two Human G Protein-coupled Receptor Genes (GPR38 and GPR39) Related to the Growth Hormone Secretagogue and Neurotensin Receptors", <i>Genomics</i> , <b>1997</b> , 17:6, pp.426-434	
*	<b>EV</b>	Nichols, J.G. et al. (eds.), "Indirect Mechanisms of Synaptic Transmission," in <i>From Neuron To Brain</i> , 3rd Edition, Sinauer Associates, Inc., <b>1992</b>	
*	<b>EW</b>	Oslo et al. (eds.), in <i>Remington's Pharmaceutical Sciences</i> , 16th Edition, Mack Publishing Co., <b>1980</b>	
	<b>EX</b>	Pauwels P.J. et al., "Review: Amino Acid Domains Involved in Constitutive Activation of G-Protein-Coupled Receptors", <i>Molecular Neurobiology</i> , <b>1998</b> , 17, pp. 109-135	
	<b>EY</b>	Seifert R et al., "Different Effects of G $\alpha$ Splice Variants on $\beta_2$ -Adrenoreceptor-mediated Signaling", <i>Journal of Biological Chem.</i> , <b>1998</b> , 273, pp. 5109-5116	
	<b>EZ</b>	Shyrock, John et al., "Inverse Agonists and Neutral Antagonists of Recombinant Human A $_1$ Adenosine Receptors Stably Expressed in Chinese Hamster Ovary Cells", <i>Molecular Pharmacology</i> , <b>1998</b> , 53, pp. 886-893	
	<b>FA</b>	Suzuki, M. et al., "Regulatable Promoters for Use in Gene Therapy Applications: Modification of the 5'-Flanking Region of the CFTR Gene with Multiple cAMP Response Elements to Support Basal, Low-Level Gene Expression that can be Upregulated by Exogenous Agents that Raise Intracellular Levels of cAMP," <i>Human Gene Therapy</i> , <b>1996</b> , 7, 1883-1893	
	<b>FB</b>	Wenzel-Seifert et al., High Constitutive Activity of the Human Formyl Peptide Receptor", <i>Journal of Biological Chem.</i> , <b>1998</b> , 273, pp. 24181-24189	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

\*A copy of this reference will not be forwarded to the U.S. Patent and Trademark Office since it is believed to be too voluminous and easily obtainable by the Examiner



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
<b>FC</b>	Noda, K., et al., "The active state of the AT <sub>1</sub> angiotensin receptor is generated by angiotensin II induction," <i>Biochem.</i> , <b>1996</b> , XP-002145163, 35, 16435-16442		
<b>FD</b>	Reppert, S.M., et al., "Cloning of a melatonin-related receptor from human pituitary," <i>FEBS Letts.</i> , <b>1996</b> , XP-002145161, 219-2254		
<b>FE</b>	Abola, A.P., et al., "Omo sapiens chromosome 13 clone RP11-286P8, complete sequence," AC026756 XP-002175912, April 24, <b>2000</b> , 1-41		
<b>FF</b>	Adams, M.D., et al., "CIT-HSP-2286K19.TF CIT-HSP homo sapiens genomic clone 2286K19, genomic survey sequence," AQ001459, XP-002175783, August 24, <b>2001</b> , 1 page		
<b>FG</b>	Birren, B., et al., "Homo sapiens chromosome 11, clone RP11-589F4," AC027026, XP002175913, April 27, <b>2000</b> , 1-40		
<b>FH</b>	Birren, B., et al., "Homo sapiens clone RP11-15H8, 31 unordered pieces," AC011780, XP002175781, October 18, <b>1999</b> , 1-46		
<b>FI</b>	Birren, B., et al., "Homo sapiens clone RP11-14N15," AC016468, XP002175784, December 1, <b>1999</b> , 1-38		
<b>FJ</b>	Boyer, J.L., et al., "Molecular cloning and expression of an avian G protein-coupled P2Y receptor," <i>Am. Soc. For Pharmacology &amp; Experimental Therapeutics</i> , XP-002175907, <b>1997</b> , 928-934		
<b>FK</b>	Burton, J., et al., "Human DNA sequence from clone RP11-163L4," A1161458, XP002175911, April 16, <b>2000</b> , 1-39		
<b>FL</b>	Burton, J., "Human DNA sequence from clone RP11-15909," AL136106, XP002175785, January 7, <b>2000</b>		
<b>FM</b>	Collier, R., "DJ68ON, 3 (G-protein coupled receptors) (fragment)," Accession Nr. Q9NTTO, XP002168498, January 10, <b>2001</b> , 1 page		
<b>FN</b>	Doe Joint Genome Institute, "Homo sapiens chromosome 5 clone CTC-502M5, complete sequence," AC008547, XP002175786, August 4, <b>1999</b> , 1-30		
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	

RECEIVED  
MAY 08 2002  
TECH CENTER 1600/2900





<b>Form PTO-449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>FO</b>	Doe Joint Genome Institute, "Homo sapiens chromosome 19 clone CTD-3023J11, complete sequence," AC008754, XP002175778, August 4, <b>1999</b> , 1-18	
	<b>FP</b>	Doe Joint Genome Institute, "Sequencing of human chromosome 5," AC008728, XP002175776, August 4, <b>1999</b> , 1-42	
	<b>FQ</b>	Gemscpue, "Drosophila melanogaster genome survey sequence TET3 end of BAC # BACRO8K10 of RPCI-98 library from drosophila melanogaster (fruit fly)," AL065769, XP00217590	
	<b>FR</b>	Hattori, M., et al., "Homo sapiens 171, 539 genomic of 11q13," AP000808, XP002175780, December 3, <b>1999</b> , 1-45	
	<b>FS</b>	Heise, C.E., et al., "Characterization of the human cysteinyl leukotriene 2 receptor," <i>J. Biological Chemistry</i> , September 29, <b>2000</b> , 275(39), 30531-30536	
	<b>FT</b>	Mahairas, G.G., et al., "Sequence-tagged connectors: A sequence approach to mapping and scanning the human genome," <i>Proc. Natl. Acad. Sci. USA</i> , August <b>1999</b> , 96, 9739-9744	
	<b>FU</b>	Marchese, A., et al., "Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology," <i>TiPS</i> , September <b>1999</b> , 20, 370-375	
	<b>FV</b>	O'Dowd, B.F., et al., "Discovery of three novel G-protein-coupled receptor genes," <i>Genomics</i> , XP-000863786, <b>1998</b> , 310-313	
	<b>FW</b>	Ohono, M., et al., "Homo sapiens mRNA for G protein-coupled receptor C5L2, complete cds," AB038237, XP002175947, May 4, <b>2000</b> , 1 page	
	<b>FX</b>	Stadel, J.M., et al., "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery," <i>TiPS</i> , November <b>1997</b> , 18, 430-437	
	<b>FY</b>	Stone, N., et al., "Homo sapiens chromosome 4, 16 unordered pieces," AC007104, XP002175914, April 23, <b>1999</b> , 1-52	
	<b>FZ</b>	Wallis, J., "Human DNA sequence from clone RP5-1160K1," AL355310, XP002175782, May 5, <b>2000</b> , 1-39	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



RECEIVED

TECH CENTER 150012901

MAY 08 2002

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office		Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
		Applicant <b>Ruoping Chen, et al.</b>	
		Filing Date <b>November 26, 2001</b>	Group <b>1646</b>
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>			
	<b>GA</b>	Waterson, R.H., "homo sapiens chromosome 2 clone RP11-510c1," AC010984, XP002175915, September 29, 1999, 1-50	
	<b>GB</b>	Weinshank, R.H., "5-hydroxytryptamine 1B receptor (-HT-1B) (serotonin receptor)," AC 008892, XP002175948, July 15, 1998, 1 page	
	<b>GC</b>	Zhao, S., et al., "Use of BAC end sequences from library RPCI-11 for sequence-ready map building," AQ532303, XP002175779, May 18, 1999, 1 page	
	<b>GD</b>	PCT International Search Report dated September 19, 2001	
	<b>GE</b>	Watson, S. et al., <i>The G-Protein Linked Receptor Facts Book</i> , Academic Press, 1994, pages 2-6 and 162-169	
	<b>GF</b>	Rudinger, J. et al., <i>Peptide Hormones</i> , ed. Parson, J.A., University Park Press, 1993, Baltimore, pages 1-7	
<b>EXAMINER</b>		<b>DATE CONSIDERED</b>	



<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
	Applicant <b>Ruoping Chen, et al.</b>	
	Filing Date <b>November 26, 2001</b>	Group <b>1646</b>

**U. S. PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Name	Class	Subclass
	<b>GG</b>	5,514,578	05/07/96	Hogness et al.	435	240.2
	<b>GH</b>	5,532,157	07/02/96	Fink	435	240.2
	<b>GI</b>	5,573,944	11/12/96	Kirschner et al.	435	252.3
	<b>GJ</b>	5,639,616	06/17/97	Liao et al.	435	7.1
	<b>GK</b>	5,750,353	05/12/98	Kopin et al.	435	7.21
	<b>GL</b>	5,861,309	01/19/99	Bard, et al.	135	325
	<b>GM</b>	5,891,720	04/06/99	Moore, et al.	435	325
	<b>GN</b>	5,955,308	09/21/99	Bergsma, et al.	435	69.1

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation YES NO	
	<b>GO</b>	2,135,253	05/08/96	Canada		
	<b>GP</b>	WO 97/11159	09/20/96	PCT		
	<b>GQ</b>	WO 97/21731	06/19/97	PCT		
	<b>GR</b>	WO 98/00552	01/08/98	PCT		
	<b>GS</b>	WO 98/34948	08/13/98	PCT		
	<b>GT</b>	WO 98/38217	09/03/98	PCT		
	<b>GU</b>	WO 98/46995	10/22/98	PCT		
	<b>GV</b>	WO 99/24569	05/20/99	PCT	X abstract	
	<b>GW</b>	WO 99/52927	10/21/99	PCT		
	<b>GX</b>	WO 00/22129	04/20/00	PCT		

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>
-----------------	------------------------



RECEIVED

<b>Form PTO-1449 Modified</b>  List of Patent and Publications Cited by Applicant (Use several sheets if necessary)  U.S. Department of Commerce Patent and Trademark Office	Docket No. <b>AREN-0308</b>	Serial No. <b>09/995,225</b>
	Applicant <b>Ruoping Chen, et al.</b>	
	Filing Date <b>November 26, 2001</b>	Group <b>1646</b>

TECH CENTER 1600/2900

MAY 08 2002

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>GY</b>	WO 01/14577 A1	03/01/01	PCT		
	<b>GZ</b>	WO 01/16159 A1	03/08/01	PCT		
	<b>HA</b>	WO 01/31014 A2	05/03/01	PCT		
	<b>HB</b>	WO 01/36471 A2	05/25/01	PCT		
	<b>HC</b>	0 612 845 A2	08/31/94	EPO		
	<b>HD</b>	0 878 542 A2	11/18/98	EPO		
	<b>HE</b>	0 892 051 A2	01/20/99	EPO		
	<b>HF</b>	1 090 989 A1	04/11/01	EPO		
	<b>HG</b>	1 094 076 A1	04/25/01	EPO		
	<b>HH</b>	8-245697	09/24/99	Japan	X abstract	
	<b>HI</b>	11-32770	02/09/99	Japan	X abstract	
	<b>HJ</b>	11-98988	09/13/99	Japan	X abstract	
	<b>HK</b>	WO 96/05302	02/22/96	PCT		
	<b>HL</b>	WO 98/29439	07/09/98	PCT		
	<b>HM</b>	WO 98/46620	10/22/98	PCT		
	<b>HN</b>	WO 98/56820	12/17/98	PCT		
	<b>HO</b>	WO 99/06552	02/11/99	PCT		
	<b>HP</b>	WO 99/32519	07/01/99	PCT		
	<b>HQ</b>	WO 99/48921	09/30/99	PCT		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		



Sheet 18 of 18

RECEIVED

**Form PTO-1449 Modified**List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)U.S. Department of Commerce  
Patent and Trademark OfficeDocket No.  
**AREN-0308**Serial No.  
**09/995,225**Applicant  
**Ruoping Chen, et al.**Filing Date  
**November 26, 2001**Group  
**1646**

TECH CENTER 1600/2900

MAY 08 2002

**FOREIGN PATENT DOCUMENTS**

Examiner Initial		Document No.	Date	Country	Translation	
					YES	NO
	<b>HR</b>	WO 00/14229	03/16/00	PCT	X abstract	
	<b>HS</b>	WO 00/22131	04/20/00	PCT		
	<b>HT</b>	WO 00/49046	08/24/00	PCT	X abstract	
	<b>HU</b>	WO 01/07606 A1	02/01/01	PCT		
	<b>HV</b>	WO 01/09184 A1	02/08/01	PCT		
	<b>HW</b>	WO 01/12673 A1	02/22/01	PCT		
<b>EXAMINER</b>				<b>DATE CONSIDERED</b>		